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The central nervous system (CNS) represents an important target for HIV infection during
multiple stages of the disease: early, after invasion of the host, acting as a viral reservoir;
lately, subverting its function and causing peripheral neuropathies and neurocognitive dis-
orders; and lastly, during the ﬁnal stage of NeuroAIDS, triggering opportunistic infections,
cancers, and dementia. Highly active antiretroviral therapy, a combination of drugs that
inhibits enzymes essential for HIV replication, can reduce the viremia and the onset of
opportunistic infections in most patients, and prolong the survival. Among the limits of the
current treatments the most noticeable is the inability to eradicate HIV-infected cells, both,
limiting the time frame in which antiretroviral therapies initiated after exposure to HIV can
prevent infection, and allowing replication-competent virus that persists in infected cells
to emerge rapidly after the cessation of treatments. Many strategies are currently under
evaluation to improve HIV treatment, unfortunately more than 98% of drug candidates for
CNS disorders never make it to the clinic; here in we report how nanoformulated strategies
might be adapted and applied to the ﬁeld of CNS–HIV infection.
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BACKGROUNG
The central nervous system (CNS) represents an important tar-
get for HIV infection during multiple stages of the disease: early,
after invasion of the host, since the virus rapidly enters the CNS,
which then constantly acts as a viral reservoir; lately, subverting its
function and causing peripheral neuropathies and neurocognitive
disorders; and lastly, during the ﬁnal stage of NeuroAIDS, trigger-
ing opportunistic CNS infections, cancers, and dementia (Tardieu
and Boutet, 2002). Highly active antiretroviral therapy (HAART),
a combination of drugs that inhibits enzymes essential for HIV
replication, can reduce the viremia and the onset of opportunistic
infections in most patients, and prolong the survival (see Table 1).
Although HAART has reduced the incidence of clinical signs of
neurological disease in HIV-infected individuals, autopsy stud-
ies suggest that there has been no corresponding decline in the
incidence of inﬂammatory lesions in the CNS.
Among the limits of the current treatments the most noticeable
is the inability to eradicate HIV-infected cells, both, limiting the
time frame in which HAART initiated after exposure to HIV can
prevent infection, and allowing replication-competent virus that
persists in infected cells to emerge rapidly after the cessation of
HAART. According to those considerations, there is evidence that
HAART is less effective in lowering virus replication in the CNS
than in the blood (Gisolf et al., 2000); andHAART resistant viruses
are more often found in the cerebrospinal ﬂuid (CSF) than in bio-
logical samples (Cinque et al., 2001). The principal challenges in
drug development for CNS–HIV infections are: (1) understanding
the pathways for viral entry, replication, reservoirs, and glial activa-
tion in order to identify new targets for treatment, (2) developing
selective therapeutics agents for those targets, or shaping effective
strategies to deliver them within the CNS, and ﬁnally but not to
underestimate (3) collaborating with pharmaceutical companies
to test promising drugs in clinical trials, and eventually exploit
them in clinical practice.
CURRENT UNDERSTANDING OF CNS–HIV INFECTION
HIV is known to productively replicate in macrophages and
microglia of the CNS, but it also infects, via a CD4-independent
pathway, macroglial cells such as astrocytes and most-importantly
brain microvascular endothelial cells, which represent the major
component of the blood brain barrier (BBB; Bissel and Wiley,
2004). Although it is generally accepted that neurons do not
become infected by HIV, recent reports have shown that neuronal
progenitor brain cells can be infected by various viral strains (i.e.,
HIV-1), eventually playing a role as viral reservoirs (Lawrence et al.,
2004). Moreover, one of the important features of CNS infection is
that its viral populations can diverge from those of plasma: indeed,
genetic compartmentalization of CSF HIV-1 infection has been
nicely demonstrated in a series of studies using the heteroduplex
tracking essay to compare blood and CSF viral populations cross-
sectionally and longitudinally (Ritola et al., 2005); therefore even
if during acute infection the two population are identical, during
chronic infection and especially in cases of HIV encephalitis they
genetically and functionally diverge, and may justify the failure of
antiretroviral therapy (Strain et al., 2005).
Identiﬁcation of viral and cellular mechanisms in the CNS that
control virus replication after acute infection, maintain latency
during the asymptomatic stage, and mediate resurgence of virus
replication and development of HIV-associated encephalitis dur-
ing late infection, is critical. The dynamic signaling pathways
that are activated by virus replication and active/inﬁltrating
macrophages and lymphocytes and the cytokines, chemokines,
and neurotoxic products they elaborate may interfere with the
homeostatic signaling pathways that maintain normal quiescent
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Table 1 | HAART currently in use in the clinical practice.
Classes of drugs Phase of the retroviral life-cycle targeted
Entry inhibitors (EIs) They interfere with binding, fusion, and entry of HIV-1 to the host cell
CCR5 receptor antagonists (CCR5RAs) They bind to the CCR5 receptor on the surface of the T-Cell and block viral attachment to the
cell. If HIV cannot attach to the cell, it cannot gain entry to replicate
Nucleoside reverse transcriptase inhibitors (NsRTIs) and
nucleotide reverse transcriptase inhibitors (NtRTIs)
They inhibit reverse transcription by being incorporated into the newly synthesized viral DNA
strand as faulty nucleotides; they both act as competitive substrate inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) They inhibit reverse transcriptase by binding to an allosteric site of the enzyme; NNRTIs act as
non-competitive inhibitors of reverse transcriptase
Protease inhibitors (PIs) They target viral assembly by inhibiting the activity of protease, an enzyme used by HIV to
cleave nascent proteins for the ﬁnal assembly of new virions
Integrase inhibitors (IIs) They inhibit the enzyme integrase, which is responsible for integration of viral DNA into the
DNA of the infected cell
Maturation inhibitors (MIs) They inhibit the last step in gag processing in which the viral capsid polyprotein is cleaved,
thereby blocking the conversion into mature capsid protein
brain function. To understand the correlates in terms of neuro-
protection, neuroinﬂammation, and neurodegeneration processes
many preclinical models have been developed, such as: HIV trans-
genic rat (i.e., tg rat from Reid et al., 2001), or mice (i.e., gp 120
tg mice from Toggas et al., 1994), but also those obtained by injec-
tion of HIV proteins (i.e., gp 120 from Sundar et al., 1991; or
Tat and Bansal et al., 2000), or HIV-infected macrophages into
the brain of mice (Anderson et al., 2003). The most studied sig-
naling pathways include, among others, the GSK3β, CDK5, ERK,
Notch, p38, and JNK cascades. For instance, it is noteworthy that
many mitogen-activated protein kinases are pivotal during acute,
asymptomatic, and terminal infection: some of them seems to
promote cell growth anddifferentiation in response to initial infec-
tion (i.e., ERK), whereas others are associated to growth arrest,
apoptosis, and oncogenic transformation duringAIDS. Those data
might explain somepeculiar characteristics of theHIV–CNS infec-
tion: in contrast to HIV-infected CD4+ T cells, infection in brain
macrophages and microglial cell lines leads to an extended life
span and elevated survival against apoptotic stresses (Chugh et al.,
2007), and only during terminal infection, when there is resurgent
virus replication, the balance favors neuronal death (i.e., via activa-
tion of JNK and p38) reﬂecting a failure to maintain homeostasis
in the CNS (Barber et al., 2004) with the consequent motor and
cognitive impairments.
DEVELOPING STRATEGIES
Many strategies are currently under evaluation to improve HIV
treatment, but a relatively small number are primarily dedicated
to the alleviation of neurological complaints or the control of Neu-
roAIDS, and unfortunately more than 98% of drug candidates for
CNSdisorders nevermake it to the clinic (Pardridge, 2003).Herein
are a couple of examples picturing how researches, initially con-
ducted for neoplastic, neurodegenerative, or epileptic disorders,
on speciﬁc pathways and delivery systems, might be adapted and
applied to the ﬁeld of CNS–HIV infection (see Figure 1).
INNOVATIVELY TARGETED PATHWAYS
Discovered in 1898, mitoguazone (MGBM) had been investi-
gated but abandoned as an anti-cancer drug, recently it was
found to cause selective loss of CD16+ HIV-infected cells,
speciﬁcally by blocking osteopontin needed to transform a cir-
culating macrophage into a CNS/resident one. MGBG although
ineffective in reducingHIVviremia,does appear to shut downviral
evolutionby selectively killing recentmigrantsmacrophages rather
than resident cells, and to be safe over the long-term treatment in
AIDS patients (Jeymohan et al., 2009).
The manipulation of IFNα and IFNγAPOBEC pathways could
prevent HIV invasion of CNS because of the potent intrin-
sic immunity exerted by the expression of APOBEC3G gene in
microvascular endothelial cells (Argyris et al., 2007). This gene
code for proteins possessing cytidine deaminase activity and allow
the BBB to actively neutralize the effects of viral infectivity factors
(Vif), which are essentials for viral entry and spread into the CNS
(Jeong et al., 2008).
NK-1, also known as Substance P, was the ﬁrst neuropeptide
discovered in 1931, it is widely distributed in the central and
peripheral nervous system where it functions as a potent mediator
of immunoregulation. Agonists to NK-1 receptor potently inhibit
both in vitro and in vivo HIV replication in human macrophages,
apparently down regulating CCR5 (Jeymohan et al., 2009).
Initially recognized, and extensively studied as a promising
target for anti-cancer therapies because of its role during tumori-
genesis, the PI3K/Akt cell survival pathway became a target for
anti-HIV treatment after the observation that PI3K inhibitors
(such as wortmannin and LY294002) or Akt inhibitors (such as
miltefosine), both able to cross the BBB, contrast the cytopro-
tective effect exerted by Tat proteins over macrophage/microglial
cells, and make them again susceptible to cell death following an
apoptotic stimulus (Chugh et al., 2007, 2008). Most interestingly
PI3K/Akt inhibitors proved to be effective without harming unin-
fected cells and therefore experimental data as far available support
their possible use for HIV-therapy and targeting of long-lived viral
reservoirs.
NANOFORMULATED HAART
NanoformulatedHAART essentiallymanipulates the immune sys-
tem for therapeutic purposes by using synthetic or biological
nanoengineered drug carriers. Those nanoformulated drugs have
been proven to be efﬁcient delivery vehicles for a wide range
of therapeutic agents, and can be easily injected in the blood
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FIGURE 1 | Mechanism of CNS–HIV infection along with the relative
therapeutic targets. 1. Selective killing of migrant macrophages (MGBM);
2. neutralization of Vif on microvascular endothelial cells (IFNα and IFNγ)
and subsequent inhibition of viral entry into the CNS; 3. inhibition of HIV
replication in macrophages and viral spread into the CNS (NK-1-agonists);
4. inhibition of cytoprotective effect exerted byTat proteins over microglial
cells which act as CNS viral reservoirs (PI3K and Akt inhibitors); 5.
protection of neural integrity and plasticity along with prevention of
neurotoxicity and neuronal death (glutamate receptors-, GSK3β-, JNK-, and
p38-inhibitors).
circulation or virtually into any site of the brain with minimal
invasiveness. Major concerns to this therapeutic approach are the
choice of drug administration (systemicor local) and consequently
the residence in the systemic blood circulation, or in the brain tis-
sue adjacent to topic injection, the drug loading efﬁciency, and the
burst release effect. Furthermore, many other question marks are
still to be answered, or even formulated.
Concerning synthetic carriers, hyaluronic acid, a linear poly-
saccharide composed of alternating d-glucuronic acid and N -
acetyl-d-glucosamine units, because of its immunoneutrality, has
been proposed as a biocompatible and biodegradable biomate-
rial for tissue engineering, and in drug delivery systems into
the CNS: particularly appealing would seem the opportunity to
produce drug-incorporated hyaluronic acid nanoparticles (Jeong
et al., 2008). As well monocytes, because of their abilities to move
drugs inside the cells have advantages as a depot for HAART,
but also they might improve compliance as drugs can be released
from cells for periods up to weeks or longer. Nevertheless, further
application of biological nanoengineered drug carriers will require
optimization of nanoparticles uptake, deeper knowledge of their
kinetics across the BBBs, and more sophisticated imaging sys-
tems to track migration of monocyte–macrophages to the brain
and target the delivery of speciﬁc therapeutics (Jeymohan et al.,
2009).
NEUROPROTECTIVE STRATEGY
Beside compounds aimed at control the virus, others try to
treat the effects of the underlying neuroinﬂammation and
neurodegeneration mechanisms, and might provide a beneﬁcial
supplement to HAART.
Neurotoxicity is mainly mediated through glutamate produc-
tion,which is triggered byNMDA subtypes of glutamate receptors,
and correlated to caspase activation and subsequent neuronal
apoptosis (Erdmann et al., 2006); accordingly, pharmacologic
inhibition of glutaminase directly correlate to neuronal survival
(Tian et al., 2008). Those insights support the hypothesis that
inhibition of glutamate production by blocking mitochondrial
glutaminase activity may clinically prevent neurotoxicity during
HIV-1 infection.
Taken together theGSK3β,CDK5, JNK,and p38 signaling path-
ways are important regulators of neurotoxicity, being responsible
for synaptic and dendritic damage to pyramidal neurons, loss of
immunoreactive neurons, and demyelinization. GSK3β inhibitors
(i.e., lithium,valproic acid) aswell asCDK5 inhibitors (i.e., roscov-
itine) seems to protect neuronal integrity and plasticity (Crews
et al., 2009), while JNK- and p38-inhibitors (i.e., minocycline)
may prevent neuronal death (Lin et al., 2001; Bozyczko-Coyne
et al., 2002) each of those target holds promise for the develop-
ment of treatment strategies to ameliorated the neuropathological
effects exerted by HIV proteins (Tat, Vif, etc.).
CONCLUSION
Combinations of drugs work better and longer than seen pre-
viously, patients beneﬁt demonstrably from the magnitude and
duration of viral suppression, and require more and more
symptomatic treatment of NeuroAIDS cognitive impairment.
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However HAART is very demanding for patients, non-adherence
can lead to therapeutic failure, and in addition drug resistance
is a continuing problem; therefore, the need for improved drug
and delivery systems, but also an interest for adaptive treat-
ment strategies and mathematical modeling to manage struc-
tured treatment interruptions (Rosenberg et al., 2007), have been
outlined by many researchers. To this regard a thigh collabora-
tion with industry is strictly required and introduces a new set
of challenges such as: (1) circulation of promising ideas, often
just developed with university grants, (2) protection of intellec-
tual property and patent rights, (3) fund-raising opportunities
for start-ups during preclinical researches on novel compounds,
until (4) identiﬁcation of potential blockbusters appealing to
Big Pharma companies for introduction in the market and their
clinical exploitation.
Finally, current criteria for initiation of HAARTdonot consider
CNS outcomes as a benchmark of efﬁcacy, thus establishing CNS-
based criteria for initiation of protocols should be the ultimate
goal not only for therapeutic but also for neuroprotection strate-
gies; as recently stated by Jeymohan et al. (2009) on behalf of the
NeuroAIDS research participants these priorities should be seen as
a template for future growth of the ﬁeld and its long-term impact.
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